Virus therapy takes on tough cancers in early trial
NCT ID NCT07190833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a modified virus called OTS-412, given alone or with hydroxyurea and the immunotherapy atezolizumab, in 27 adults with solid tumors that have stopped responding to standard treatments. The main goal is to check safety and side effects, while also looking at whether the tumors shrink. It is too soon to know if this approach will work, but it may offer a new avenue for patients with few options left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OTS-412 (a modified vaccinia virus), hydroxyurea, and atezolizumab
- What this could lead to
- If it works, this could point toward a new treatment option for patients with solid tumors that no longer respond to standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 27 participants, so it is primarily testing safety. The virus and drug combination may not shrink tumors or improve survival, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dong-A University Hospital
RECRUITINGBusan, 49201, South Korea
-
Pusan National University Yangsan Hospital
RECRUITINGBusan, 50612, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.